scholarly journals Erratum to: Galectin-3: A factotum in carcinogenesis bestowing an archery for prevention

Tumor Biology ◽  
2021 ◽  
Vol 43 (1) ◽  
pp. 307-307
Keyword(s):  
2020 ◽  
Vol 134 (1) ◽  
pp. 71-72
Author(s):  
Naseer Ahmed ◽  
Masooma Naseem ◽  
Javeria Farooq

Abstract Recently, we have read with great interest the article published by Ibarrola et al. (Clin. Sci. (Lond.) (2018) 132, 1471–1485), which used proteomics and immunodetection methods to show that Galectin-3 (Gal-3) down-regulated the antioxidant peroxiredoxin-4 (Prx-4) in cardiac fibroblasts. Authors concluded that ‘antioxidant activity of Prx-4 had been identified as a protein down-regulated by Gal-3. Moreover, Gal-3 induced a decrease in total antioxidant capacity which resulted in a consequent increase in peroxide levels and oxidative stress markers in cardiac fibroblasts.’ We would like to point out some results stated in the article that need further investigation and more detailed discussion to clarify certain factors involved in the protective role of Prx-4 in heart failure.


2013 ◽  
Author(s):  
Wawrzyniak Andrew J. ◽  
Kerry S. Whittaker ◽  
Sarah M. Godoy ◽  
Kristie M. Harris ◽  
Maria N. Banis ◽  
...  

2008 ◽  
Vol 46 (10) ◽  
Author(s):  
E Lippert ◽  
M Stieber-Gunckel ◽  
C Hofmann ◽  
N Dunger ◽  
W Falk ◽  
...  
Keyword(s):  

2016 ◽  
Vol 64 (S 02) ◽  
Author(s):  
L. Calvier ◽  
E. Legchenko ◽  
L. Grimm ◽  
H. Sallmon ◽  
A. Hatch ◽  
...  

2019 ◽  
Author(s):  
S. Klein ◽  
I. Nolte ◽  
E.-M. Packeiser ◽  
N. Iwanuk ◽  
K. Rumstedt ◽  
...  
Keyword(s):  

2005 ◽  
Vol 43 (10) ◽  
Author(s):  
E Lippert ◽  
F Bataille ◽  
M Hausmann ◽  
S Kellermeier ◽  
W Falk ◽  
...  
Keyword(s):  

2006 ◽  
Vol 44 (08) ◽  
Author(s):  
E Lippert ◽  
J Brenmoehl ◽  
W Falk ◽  
J Schölmerich ◽  
G Rogler
Keyword(s):  

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.


Sign in / Sign up

Export Citation Format

Share Document